» Articles » PMID: 25142481

Quantifying Comorbidity in Individuals with COPD: a Population Study

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2014 Aug 22
PMID 25142481
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic obstructive pulmonary disease (COPD) has been associated with many types of comorbidity. We aimed to quantify the real world impact of COPD on lower respiratory tract infection, cardiovascular disease, diabetes, psychiatric disease, musculoskeletal disease and cancer, and their impact on COPD through health services. A population study using health administrative data from Ontario, Canada, in 2008-2012 was conducted. Absolute and adjusted relative rates of ambulatory care visits, emergency department visits and hospitalisations for the comorbidities of interest in people with and without COPD were determined and compared. Among 7 241 591 adults, 909 948 (12.6%) had COPD. Over half of all lung cancer, a third of all lower respiratory tract infection and cardiovascular disease, a quarter of all low trauma fracture, and a fifth of all psychiatric, musculoskeletal, non-lung cancer and diabetes ambulatory care visits, emergency department visits and hospitalisations in Ontario were used by people with COPD. Individuals with COPD used about five times more health services for lung cancer, and two times more health services for lower respiratory tract infections and cardiovascular disease than people without COPD. Individuals with COPD use a disproportionate amount of health services for comorbid disease, placing significant burden on the healthcare system.

Citing Articles

Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts.

Cazzola M, Calzetta L, Rogliani P, Matera M Int J Chron Obstruct Pulmon Dis. 2024; 19:2481-2495.

PMID: 39606712 PMC: 11600434. DOI: 10.2147/COPD.S498255.


Baseline patient demographics for TETRIS: a prospective, noninterventional study to characterize the use of triple therapy for COPD in Germany.

Vogelmeier C, Beeh K, Kardos P, Paulsson T, Rohde G, Watz H Ther Adv Respir Dis. 2024; 18():17534666241287621.

PMID: 39436955 PMC: 11526303. DOI: 10.1177/17534666241287621.


Cardiovascular Risk in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review.

Sa-Sousa A, Rodrigues C, Jacome C, Cardoso J, Fortuna I, Guimaraes M J Clin Med. 2024; 13(17).

PMID: 39274386 PMC: 11396696. DOI: 10.3390/jcm13175173.


Quantifying sustained health system benefits of primary care-based integrated disease management for COPD: a 6-year interrupted time series study.

Licskai C, Hussey A, Rowley V, Ferrone M, Lu Z, Zhang K Thorax. 2024; 79(8):725-734.

PMID: 38889973 PMC: 11287652. DOI: 10.1136/thorax-2023-221211.


An economic evaluation of chronic obstructive pulmonary disease clinical pathway in Saskatchewan, Canada: Data-driven techniques to identify cost-effectiveness among patient subgroups.

Kuwornu J, Maldonado F, Groot G, Cooper E, Penz E, Sommer L PLoS One. 2024; 19(4):e0301334.

PMID: 38557914 PMC: 10984414. DOI: 10.1371/journal.pone.0301334.